subject an effective amount of a polypeptide in accordance with claim 1 or 2.

23(Twice Amended). A method according to claim 22, wherein administering the polypeptide causes the target cell to present a CTL epitope which is foreign to the target cell.

REMARKS

In accordance with the above-amendments, claims 1, 2, 9, 21 and 23 have been amended to indicate the number of times they have been amended and, in the case of claims 1 and 2, to add the proper SEQ ID Nos.

These amendments should bring the earlier Amendment into full compliance as a complete response. Reconsideration and early allowance of the claims is respectfully requested.

Should issues remain which in the opinion of the Examiner can be resolved by telephone interview, the Examiner cordially requested to contact the undersigned attorney in order to resolve same and expedite prosecution of this application.

Respectfully submitted,

NIKOLAI & MERSEREAU, P.A.

C. G. Mersereau

Registration No. 26,205

Attorneys for Applicant(s)

820 International Centre

900 Second Avenue South

Minneapolis, MN 55402

(612) 339-7461

CERTIFICATE OF MAILING

I hereby certify that the foregoing Supplemental Amendment in response to the Official Communication of July 15, 2002 in application Serial No. 08/737,457, filed on March 12, 1997 of Donald L.N. Cardy et al., entitled "IMPROVEMENTS IN OR RELATING TO PEPTIDE DELIVERY", and a transmittal letter are being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to The Commissioner of Patents and Trademarks, Washington, D.C. 20231, on July 30, 2002.

Barbara L. Davis

Secretary to C. G. Mersereau

Date of Signature: July 30, 2002

Marked-up Version of Claims Being Amended

- 1 (Five Times Amended). A chimaeric polypeptide comprising:
- (a) a scFv having specific binding affinity for a eucaryotic target cell surface component;
- (b) an effector portion comprising at least one copy of an immunogenic peptide having the sequence KYICNSSCM SEQ ID NO. 7 or GILGFVFTL SEQ ID NO. 8; and optionally
- (c) a signal derived from the translocation domain of HIV tat protein directing the immunogenic peptide to a particular cellular component, whereby binding of the chimaeric polypeptide to the cell surface component induces internalisation of at least the effector portion to allow the at least one copy of the immunogenic peptide to be presented by MHC molecules on the target cell surface.

2 (Three Times Amended). A chimaeric polypeptide comprising: a scFv, from a first source, having specific binding affinity for a eukaryotic target cell surface component; an effector portion, from a second source, comprising; at least one copy of an immunogenic peptide having the sequence KYICNSSCM SEQ ID NO. 7 or GILGFVFTL SEQ ID NO. 8, and a translocation portion derived from the translocation domain of HIV tat protein, the translocation portion being adjacent to the effector portion; whereby binding of the polypeptide to the cell surface component induces

internalization of at least the effector and translocation portions so as to allow the effector portion to enter the cytosol of the target cell and hence all the peptide to induce cell lysis.

9 (Four Times Amended). A polypeptide according to claim 1 or 2 wherein the effector portion comprises a number of repeats of the same peptide.

21(<u>Five Times Amended</u>). A method of stimulating cell lysis of a human or animal subject, comprising administering to the subject an effective amount of a polypeptide in accordance with claim 1 or 2.

23(<u>Twice</u> Amended). A method according to claim 22, wherein administering the polypeptide causes the target cell to present a CTL epitope which is foreign to the target cell.